Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 2 long-term extension study of glepaglutide in short bowel syndrome
NL-OMON59108Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Apr 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Primary endpoints: Incidence and type of adverse events, Incidence and type of serious adverse events and adverse events of special interest and 10 more. Started Apr 2019; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NL-OMON59108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59108.